Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Phase 3 Completed 26 enrolled Ohio State University Food and Drug Administration (FDA) · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD

Timeline

Start: 2007-11
Primary completion: 2017-09-20
Completion: 2017-09-20

Publications

Cataland SR, Kourlas PJ, Yang S, Geyer S, Witkoff L, Wu H, Masias C, George JN, Wu HM. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. Blood Adv. 2017 Oct 23;1(23):2075-2082. doi: 10.1182/bloodadvances.2017009308. eCollection 2017 Oct 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclosporine	Peptide	2 mg/kg	Oral
Subject	Cyclosporine	Peptide	3 mg/kg	Oral
Comparator	Prednisone	Other / unclassified	1 mg/kg	Oral

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Summary

Timeline

Publications

Drugs

Indications